Greetings, and welcome to the Edwards Lifesciences third quarter 2023 earnings conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mark Wilterding, Senior Vice President, Investor Relations and Treasurer. Thank you. You may begin. Thank you very much, Diego, and good afternoon, and thank you all for joining us. We are coming to you live from San Francisco at the 35th annual TCT conference. With me on today's call is our CEO, Bernard Zovighian, and our CFO, Scott Ullem. Also joining us for the Q&A portion of the call are Larry Wood, our Group President, excuse me, of TAVR and Surgical Structural Heart, and Daveen Chopra, our Global Leader of TMTT. Just after the close of regular trading, Edwards Lifesciences released third quarter 2023 financial results. During today's call, management will discuss those results included in the press release and accompanying financial schedules, and then use the remaining time for Q&A. Please note that management will be making forward-looking statements that are based on estimates, assumptions, and projections. These statements include, but aren't limited to, financial guidance and expectations for longer-term growth opportunities, regulatory approvals, clinical trials, litigation, reimbursement, competitive matters, and foreign currency fluctuations. These statements speak only as of the date on which they were made, and Edwards does not undertake any obligation to update them after today. Additionally, the statements involve risks and uncertainties that could cause actual results to differ materially. Information concerning factors that could cause these differences and important safety information may be found in the press release, our 2022 annual report on Form 10-K, and Edwards' other SEC filings, all of which are available on the company's website at edwards.com. Unless otherwise noted, our commentary on sales growth refers to constant currency sales growth, which is defined in the quarterly results press release issued earlier today. Reconciliations between GAAP and non-GAAP numbers mentioned during the call are also included in today's press release. With that, I'd like to turn the call over to Bernard for his comments. Good afternoon, everyone. As Mark said, you know, we are hosting today's call from TCT in San Francisco. I am going to start by covering some of the exciting developments at the conference, share highlights of the significant progress our team has made advancing our strategy, review our strong third quarter results, and finally, discuss our confidence in the outlook for Edwards. There are a lot of data being presented this week about technologies Edwards has developed. Included among these are results from three late-breaking clinical trials, all of which reflects Edwards' commitment to generating high-quality evidence to advance innovative therapies for patients suffering from structural heart disease. Yesterday, physicians presented five year data from the PARTNER 3 low-risk pivotal trial. We believe these data demonstrate that TAVR, with the SAPIEN platform, should continue to be the preferred therapy for treating patients who have severe symptomatic aortic stenosis. After more than 20 years of rigorous clinical experiences and trials, now 8 New England Journal of Medicine publications and over 1 million patients treated, SAPIEN technology offers patients unique benefits. SAPIEN 3 has demonstrated 99% freedom from death and disabling stroke at one year, 90% survival at five years, and is the only valve with a THV-in-THV indication. This is true lifetime management benefit, which expands options for patients. Tomorrow, at TCT, we are looking forward to the presentation of the 6-month analysis of our EVOQUE transcatheter tricuspid valve, the first of its kind therapy for the millions of patients suffering from tricuspid valve disease. In addition, tomorrow, you will see the one year full cohort result of a Class II D pivotal trial with PASCAL. We continue to make meaningful progress to advance our vision of offering a portfolio of innovative transcatheter therapies to treat tricuspid and mitral valve disease. In the last several weeks, we achieved four important milestones in support of our commitment to patient-focused innovation. First, CE Mark approval for the EVOQUE transfemoral replacement system. Second, CE Mark approval for the MITRIS RESILIA surgical mitral valve. Third, PASCAL Precision approval in Japan. Finally, the completion of the enrollment in the first-ever pivotal trial for any transfemoral mitral replacement therapy, the ENCIRCLE trial for SAPIEN M3. Turning now to Q3 financial performance. Third quarter global sales grew 11% to $1.5 billion, led by our differentiated portfolio of innovative therapies. We were pleased with the results, which were in line with our expectation and represent another quarter of double-digit sales growth. For the full year, we continue to expect total company sales growth to be in the 10%-13% range. Now, I will provide an overview of the third quarter sales performance by product group. In TAVR, we continue to see strong demand for our leading SAPIEN platform, with third quarter sales of $961 million, up 10% year-over-year. Our US and OUS sales growth rates were comparable. Our US and OUS competitive positions were stable, and globally, local selling prices were stable. In the US, our third quarter TAVR sales were driven by the continued successful launch of SAPIEN 3 Ultra RESILIA. On the clinical side, we are pleased with the pace of enrollment in our pivotal trial ALLIANCE, designed to study SAPIEN X4, our groundbreaking next generation TAVR technology. In Europe, Edwards' sales growth was driven by the broad-based adoption of our SAPIEN platform. We look forward to additional data supporting the Edwards Benchmark Program to be presented at the PCR London Valves Conference in November. Our sales in Japan grew year-over-year, reflecting a gradual recovery in market growth and strong adoption of SAPIEN 3 Ultra RESILIA. Competitive trialing in the third quarter was less pronounced versus in the first half of this year, and as expected, we grew faster than overall procedural growth. Around the world, we remain focused on improving diagnosis and treatment of the many more patients who remain undertreated. In summary, the combination of our global TAVR leadership, along with the data presented at TCT this week, gives the company further confidence in the future of TAVR and the company's expectation of a $10 billion opportunity by 2028. Now, turning to TMTT. Our commitment to the unmet needs of mitral and tricuspid patients took a significant step forward with the achievement of several important milestones in this past quarter. TMTT third quarter global sales of $52 million increased 65% versus the prior year. This performance was driven by accelerating adoption of our differentiated PASCAL Precision platform, the activation of more centers across the U.S. and Europe, as well as TEER procedural growth. We continue to be pleased with our excellent clinical outcomes, reflecting the impressive performance of PASCAL Precision and the value brought by our comprehensive high touch model. We are continuing the expansion of PASCAL Precision globally, with the expected launch in Japan before the end of the year. In our mitral clinical trials, we look forward to the one year CLASP IID randomized pivotal trial, and CLASP IID registry outcomes with PASCAL to be presented as part of a late-breaking scientific sessions tomorrow at TCT. This will add to the body of evidence supporting TEER as an effective therapy for patients. With the earlier than expected completion of enrollment in the ENCIRCLE pivotal trial for SAPIEN 3, we believe we are one step closer to offering an important valve replacement option beyond TEER, to serve even more patients suffering from mitral valve disease. In TRISCEND, earlier this month, we received CE Mark approval for EVOQUE. We look forward to bringing this new therapy to Europe through a disciplined launch that will focus on ensuring excellent patient outcomes. Now, with this approval, physicians in Europe will have access to this groundbreaking option in addition to TEER. As noted, tomorrow at TCT, late-breaking data from the TRISCEND II pivotal trial of the EVOQUE replacement technology will be presented on the first 150 randomized patients based on EVOQUE's FDA breakthrough pathway designation. This landmark presentation on a novel therapy demonstrate our leadership and commitment to innovation and science, and our focus on helping large population of patients with unmet needs. In summary, for TMTT, we are proud of the new therapy introductions, clinical trial achievements, and geographic expansion we have achieved to advance our vision to build a portfolio of therapies to transform the lives of mitral and tricuspid patients. In Surgical, third quarter sales of $247 million increase 11%, driven by a balanced combination of strong global adoption of Edwards premium technology and overall procedure growth. We continue to see strong momentum of our RESILIA portfolio globally, which has been widely adopted because of the excellent durability of its proven tissue technology, supported by the recent seven year aortic data and five year mitral data from our COMMENCE clinical trial. We are confident about the future of this technology as we expand the overall body of RESILIA evidence, including ongoing patient enrollment of our MOMENTOUS clinical study. Finally, we received CE Mark approval for our MITRIS RESILIA mitral valve earlier this month. We expect to introduce this valve in the fourth quarter, followed by full European launch in 2024. In critical care, third quarter sales of $221 million increased 6%, driven by our smart recovery portfolio, with strong adoption of our Acumen IQ sensors, equipped with the Hypotension Prediction Index algorithm. We remain confident in our pipeline of critical care innovation as we continue to shift our focus to smart recovery technologies designed to help clinicians make better decisions and get patients home to their family faster. Now I will turn the call over to Scott. Hey, thanks a lot, Bernard. We are pleased to report third quarter sales performance in line with our expectations, with strength across all product groups. We achieved total sales of $1.48 billion, which represents 11% year-over-year growth. We achieved adjusted earnings per share of $0.59. Our GAAP earnings per share of $0.63 benefited from a change in U.S. tax regulations. A full reconciliation between our GAAP and adjusted earnings per share for this and other items is included with today's release. I'll now cover some additional details of our third quarter sales results and full year 2023 outlook by product group. A continuation of double-digit global TAVR growth reflected a more balanced hospital staffing environment, as well as strong adoption of the SAPIEN family of valves. U.S. TAVR sales growth was driven by the launch of SAPIEN 3 Ultra RESILIA, which remains on track to represent the majority of our U.S. TAVR sales before year-end. In Europe, Edwards sales growth was driven by the continued demand of our SAPIEN platform and was broad-based by country. In Japan, improved growth in the third quarter was driven by the ongoing launch of our SAPIEN 3 Ultra RESILIA valve. For global TAVR sales, we continue to expect full year 2023 sales of $3.85 billion-$4.0 billion, representing 10%-13% growth. TMTT growth in Q3 was driven by adoption of our differentiated PASCAL Precision platform, activation of more centers across the U.S. and Europe, and strong procedure volumes. Overall, we are pleased with our continued progress towards establishing a portfolio of TMTT therapies, combined with contemporary clinical data, in order to achieve our vision of transforming the lives of patients with mitral and tricuspid valve disease. We continue to expect full year 2023 TMTT sales of $180 million-$200 million. In surgical structural heart, 11% sales growth in the quarter was driven by the adoption of Edwards RESILIA products. Based on positive year-to-date performance, we continue to expect that our full year sales will be in the range of $960 million-$1.02 billion, implying low double-digit growth in 2023. In critical care, we continue to expect full year 2023 sales of $870 million-$940 million. For total Edwards, based upon the performance we have delivered year to date, we continue to expect full year 2023 sales to be in the range of $5.9 billion to $6.1 billion and full year sales growth to be in the 10%-13% range. Lastly, we continue to expect our full year adjusted earnings per share to be between $2.50 and $2.60. We're projecting fourth quarter sales to be between $1.45 billion-$1.53 billion. We are also projecting fourth quarter adjusted earnings per share to be between $0.60 and $0.66. Now I'll cover additional details of our PNL. For the third quarter, our adjusted gross profit margin was 76.4%, as expected, compared to 81% in the same period last year. This year-over-year reduction was driven by impacts from foreign exchange. Remember, last year, Edwards' gross profit margin was lifted by an unusually positive impact from foreign exchange. We continue to expect our full-year 2023 adjusted gross profit margin to be between 76%-78%. Selling general and administrative expenses in the quarter were $440 million, or 29.7% of sales, compared to $377 million in the prior year. This increase was driven by investments in transcatheter field-based personnel in support of our growth strategy and performance-based compensation. We continue to expect full year 2023 SG&A as a percent of sales to be 29%-30%, as we invest in field-based personnel and our therapy adoption initiatives. Research and development expenses in the third quarter grew 16% over the prior year to $270 million, or 18.3% of sales. This increase was primarily the result of continued investments in our transcatheter valve innovations, including increased clinical trial activity. For the full year 2023, we continue to expect R&D to be 17%-18% of sales, as we invest in developing new technologies and generating evidence to support TAVR and TMTT. Turning to taxes, our reported tax rate this quarter was 12.7%, or 18.8%, excluding the impact of special items. Our reported rate benefited from the suspension of certain U.S. tax regulations surrounding foreign tax credits. Our slightly higher than expected non-GAAP rate resulted primarily from income mix and a lower excess tax benefit from stock-based compensation. We continue to expect our full year tax rate, excluding special items, to be between 13% and 17%. Foreign exchange rates decreased third quarter reported sales growth by 140 basis points, or $16 million, compared to the prior year. At current rates, we now expect an approximately $40 million year-over-year negative impact to full year 2023 sales compared to 2022. FX rates negatively impacted our third quarter gross profit margin by 410 basis points compared to the prior year. Relative to our July guidance, FX rates had a $0.01 negative impact on third quarter earnings per share. Free cash flow for the third quarter was $356 million, defined as cash flow from operating activities of $411 million, less capital spending of $55 million. We continue to expect full year 2023 adjusted free cash flow will be between $1.0 billion and $1.4 billion. Before turning the call back over to Bernard, I'll finish with an update on our balance sheet and share repurchase activities. We continue to maintain a solid and flexible balance sheet with approximately $1.9 billion in cash, cash equivalents, and short-term investments as of September 30. During the third quarter, we repurchased 2.2 million shares under our 10b5-1 plan. We continue to expect average diluted shares outstanding for 2023 to be between 610 and 615 million. We have approximately $500 million remaining under our current share repurchase authorization. With that, back over to you, Bernard. Thank you, Scott. In closing, after more than 20 years of vigorous clinical experience, over 1 million patients treated, and this week's, you know, five year PARTNER 3 results, Edwards TAVR is positioned for strong, sustainable growth as many patients remain undiagnosed and untreated. In addition, we have two strong global businesses, critical care and surgical, which are positioned for durable long-term growth, driven by portfolios of differentiated technology. Moreover, we are achieving many, many significant milestones in TMTT that gives us, you know, the confidence about progressing our vision to treat the many mitral and tricuspid patients in need. Altogether, we are convinced of the tremendous opportunity to drive success in the future through our patient focus, breakthrough technologies, and leadership. With that, pass it back to Mark to open up Q&A. Thank you very much, Bernard. Before we open it up for questions, I'd like to remind you about our 2023 investor conference, which we will host at our headquarters in Irvine, California, on Thursday, December 7. This event will include updates on our latest technologies, views on longer-term market potential, as well as our outlook for 2024. More information and a registration form are available on our website. With that, we're ready to take questions now. In order to allow for broad participation, we ask that you please limit the number of questions to one, plus one follow-up. If you have additional questions, please reenter the queue, and management will answer as many participants as possible during the remainder of the call. Diego, please go ahead with additional details on accessing the Q&A portion of the call. Thank you. If you'd like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we pull for questions. Our first question comes from Robbie Marcus with JP Morgan. Please state your question. Oh, great. Thanks for taking the question. Maybe to start, you guys did 11% TAVR growth in the quarter, roughly similar US, OUS. How do we think about what's holding it back here from being faster? You know, pre-COVID, it was growing at much higher rates. It's been one of the slower to recover subsectors in med tech. Data you present this weekend should be supportive of growth, but what gives you confidence this can remain a double-digit growth market for the foreseeable future? Thank you, Robbie. You know, let me start, and then I will ask, you know, Larry, you know, to continue here. First, you know, we are pleased, you know, to this quarter. Again, it is the third quarter in a row of double digits, you know, sales growth. You know, we are very pleased about it. Very balanced, you know, between US and OUS. Our ultra adoption is going very well, according to plan, in US and in Japan. And we look at the opportunity with, you know, so many patients are undiagnosed and untreated. So we feel good about, you know, what's ahead of us. We feel that we are well positioned. All of the data, you know, presented this week give us, you know, even, you know, greater confidence. But Larry, you want to add anything? Yeah, I, I don't have a lot to add. You know, this is our third straight quarter of double-digit growth, which, you know, coming out of COVID and, and all the rockiness that we saw during that period of time, it's, it's actually been really good to see the stability that we've seen and the continued growth, even as our business gets larger. So I, I actually feel really good about our growth rate. I think, you know, we're continuing to work to get patients off the sidelines and our patient activation. I think the data, you know, hopefully the data here is, is reassuring for patients. You know, people were worried about a durability signal with TAVR, and now we have, you know, really high quality data published with the New England Journal of Medicine, that shows absolutely no durability signal at five years using BARC-3 definitions. So we think all of those are positive, and those continue to help us have, you know, double digit and sustainable growth over a long period of time. So I feel great about where we are. Great. Maybe one more product question here from me. You just got EVOQUE approved in Europe with CE Mark. We'll see the data for six months tomorrow in tricuspid replacement. This is a market we hear from doctors a lot. They may not be terribly excited about repair, but replacement could be a really exciting option. What do you think Edwards needs to do as a company to take this market and accelerate adoption and drive uptake here in an area that's been pretty slow with tricuspid repair? Thanks. Thank you, Robbie. So we are going to do, you know, what we have done in TAVR for the last, you know, 15 years. You know, basically, focusing on number one of the patient outcomes. So which is why, you know, we are going to be focusing on making sure, you know, our team is well trained, you know, well equipped, you know, to support the physicians. We are going to have a disciplined launch, you know, in Europe, and we are going to produce evidence like, you know, the TRISCEND II cohort you are going to see, you know, tomorrow, and we are going to continue to produce, you know, more evidence. But maybe, Daveen, you want to add anything here? Yeah, no, thanks, Bernard. I appreciate it. No, I, I think as Bernard has said, we really do believe that it's the comprehensive high touch model and outstanding outcomes is a key step. But it's, it's much more than that, and us having the ability to take the TAVR playbook from, from long ago and help apply it to this new area is really important. And for us, that includes not only technology, innovation, evidence, but also continuing to then over time, work on helping improve, diagnosis, referral, and eventually treatment of patients. But for us, this is a comprehensive kind of, play, long-term play for us to really build a new therapy that we're really excited about to help patients with. If I may add, you know, Robbie here, we, we are also, you know, at the beginning of, you know, better understanding, you know, this tricuspid, this tricuspid disease. We believe that with TEER and a replacement option, physician will have, you know, more options to treat, you know, even more patients. So we are going to learn a lot here about, you know, what therapy for what patient. But I think TEER therapy in Europe and U.S., you know, leading that, you know, space, we are going to learn a lot in the past, you know, few years, and I'm sure, you know, patients will benefit from that. Thank you. Our next question comes from Larry Biegelsen with Wells Fargo. Please state your question. Good afternoon. Thanks for taking the question. Scott, year to date, the TAVR growth is a little over 10%, I believe, and midpoint of the guidance is about 11.5%. So should we be thinking about the low end of the TAVR range of 10%-13% for the year? And if not, what drives the, you know, acceleration implied in Q4 for TAVR? And I have one follow-up. Well, I'd take it back to the beginning of the year, when our guidance for the full year for both TAVR and Edwards was 9%-12%. We increased it to ultimately 10%-13% because of the first quarter and the second quarter results. So we're coming in about where we thought we would for Q3 and Q4. The ten to thirteen percent guidance reflects the stronger than expected Q1 and Q2. You know, in the fourth quarter, our guidance for the full company is about $10 million higher at the midpoint than our results in Q3. So we haven't broken out guidance by business unit, but you can expect that overall, we expect a fourth quarter that looks pretty similar to the third quarter. You're right, I think for the full year, we're probably gonna end up about in the middle of the range that we said, 10%-13%, but that doesn't mean that it's 10%-13% for Q4, because again, that higher range reflects the increase from the first quarter. Thank you for that. And obviously, people are starting to think about 2024 right now. So Bernard, at our conference, you talked about targeting double-digit annual revenue growth. Does that apply to 2024? And Scott, you know, 2023 guidance implies margins are down year-over-year because of investments and currency. You know, what are some of the push and takes on the P&L, you know, that we should be thinking about it, and any help on FX would be appreciated. Thank you. Thank you, Larry. Let me take, you know, the first part of your question here. So for, you know, 2024 guidance, you know, you will get, you know, all of the details, you know, in December at our investor event. And if the question is about, you know, my confidence and our confidence as a company, yes, we are confident. As I said, you know, during, you know, the script, you know, I think like we have an amazing opportunity in front of us with so many patients.... all of our businesses are in solid position, in global leadership position. So I am confident for the years to come, for 2024, you know, more to come in December, Larry. Larry, it's Scott. For the second part of your question about FX, you know, we'll talk about more of the specifics at the investor conference, but if you take our exchange rate environment right now and apply it to 2024, it would be a headwind to sales and also a headwind to EPS. So we'll be able to quantify that more specifically, and, you know, we'll see what happens to FX rates between now and then as well. All right. Thank you, guys. Our next question comes from Vijay Kumar with Evercore ISI. Please state your question. Hey, guys. Thanks for taking my question. Bernard, maybe a first one for you on the SAPIEN 3. Five year data that was presented, a lot of noise in the street on the lines crossing for Edwards and your peer, the lines widening between TAVR and Control. Does that worry you at all, just from Edwards' perspective when you look at the data? And I think you also mentioned BARC definition for durability. Is that something that your peer also uses the same definition or are there some differences here in how durability was defined in these two trials? Thank you, Vijay. You know, let me start, you know, high level. I believe, you know, last night, you know, investor event was, you know, very insightful with Dr. Leon and Dr. Mark. You know, they went, you know, very deep into the data. They went, you know, very deep into the meaning, you know, the meaning of the data and the trial design. At the end of the day, you know, for me, it is... You know, I like to keep it, you know, very simple. 90% survival at five years, that's amazing, you know, for patients. That's, you know, in my mind, you know, what we should remember. But I'm going to ask, you know, Larry to comment, you know, and with greater detail here. Yeah. Thanks, Bernard. Yeah, this, this whole thing about the curves continuing to diverge just isn't really accurate. I think we had a little bit of a catch-up, but if you'll notice from the New England Journal of Medicine manuscript, you know, we are impacted somewhat by the patients that withdrew on the surgical side disproportionately. And when we did the phone sweep, the absolute difference that we're showing at five years is about 1%. When you go into the causes of death, you know, you look at cardiovascular mortality, they're about the same. We had, I think, double the rate of cancer. We had three times as much Covid death in the TAVR group as we had in the surgical group, and I think higher rates of sepsis, which we all adjudicate to be not TAVR related. I don't think anybody's suggesting that TAVR causes cancer or COVID. So when you get into the depths of the data, I mean, we feel great about the data. What's amazing about this data set is that both groups performed incredibly well. And, given the prominence of Edwards surgical valves, and then obviously, you know, our TAVR cohort, you know, we're looking at both groups that have over 90% survival at five years. And the other thing that people have been worried about with TAVR was durability. And you're right, we did use the BARC definitions for durability, which, you know, remember, isn't what surgery has historically used. Surgery historically has used freedom from explant due to structural valve deterioration, not echo-derived criteria. And so, you know, part of what drives the New England Journal of Medicine publication is we used all the contemporary standards, all the contemporary things. So, you know, I don't want to comment on other people's data. You can, you can ask them about their data and what methodologies they use, but I'm very comfortable we applied the highest academic standards to our study. And again, we feel great about the data. And I think there's, there's just a little bit of an oddity here that, that people are discussing, that somehow TAVR has to be better than surgery. If we have two procedures, TAVR and surgery, and we can go to patients and say, "Your results are identical at five years," then that's gonna automatically default people to the less invasive therapy. And now we need to continue to follow these patients. We need to follow them all the way out to 10 years. But, you know, for a pretty significant interim look at the data at five years, I don't think we could be any happier about the data than we are. In addition, Vijay, you know, if you think about what we have been saying all along about, you know, the under diagnosis and under treatment of this patient. Now, you look at this part of the three to five years, we hope, we certainly hope that, you know, that, you know, the referring, you know, network of cardiologists will send, you know, more patients because, you know, they have options, safe options, effective options. So we, we feel good about all of this. Yeah. I mean, I'll just add, I think this was a great day, you know, a great meeting for the field in general. You know, if you have patients on the sidelines who say, "You know, I'm just—I just don't want to have open heart surgery. I'm too scared of open heart surgery," but they're being told, "You know, TAVR doesn't really have any data behind it, and it's still early." You know, if you look at both data sets that were presented, there's absolutely no durability signal at five years or four years, depending on which study you're looking at. And I think that should just give the referral community tremendous confidence that they can send patients for this procedure, and they're gonna get a durable outcome. That's helpful, guys. And Bernard, just one more for you. There were some headlines on investigation in Europe. Any financial implications here? It's just the headlines look a little odd. And I know it's a silly question, but I have to ask, is there any GLP-1 exposure to TAVR or TAVR patients related to based in GLP-1? Thank you. Oh, thanks. You know, in Europe, you know, there is, you know, no financial exposure. You know, we had a, you know, a brief, you know, statement on that, you know, so no expectation here. With regards to GLP-1 exposure to TAVR, we don't think so. You know, we have not seen any evidence that, you know, losing weight has any impact to aortic stenosis disease. We don't, we don't know that. We don't see that. We don't... We have not seen any evidence. So we, so we don't see any possible implication here. Larry, anything to add? No, I totally agree. I think, you know, as it relates to just general things, you know, obviously people losing weight is a good thing, but we've never seen anything related to even, you know, even coronary disease. You know, there's a lot of these things are genetically derived and genetically driven, and I don't think your, your weight is gonna be the determinant of, of those things. So I don't, I don't really see any impact of this. Thanks, guys. Our next question comes from Josh Jennings with TD Cowen. Please state your question. Hi, good afternoon. Thanks for taking the questions. I wanted to just ask first on the tricuspid repair and replacement segment, and just get your views on patient-reported outcomes, driving approvals, and potentially reimbursement decision, positive reimbursement decisions. Are patient-reported outcomes or quality of life improvements enough to clear those two hurdles? So let me start, and then I'm sure, you know, Daveen can add, you know, his thoughts. It is a good start. You know, we have seen TRILUMINATE so far, correct? And we believe, you know, TRILUMINATE was a good study, good outcome for patients, safe, with great quality of life improvement for this patient who have a miserable life. We need to remember that. With EVOQUE, you know, we are going to talk about it tomorrow, so it is tough for me to talk about it today. We might talk about it more, you know, at the end of the day tomorrow at our investor conference. But at the end of the day, you know, quality of life improvement are important. Solid, you know, safety profile also is important. And all of that, we see that as a great, you know, start, you know, for this patient who have no other options today. Daveen, you want to add anything? Yeah, I mean, I think we continue to see out of our European experience, where we do have PASCAL tricuspid approved, that we continue to see these great outcomes where the technology is really making a difference in patients' lives. It's taking patients that ultimately can't do the things they wanna do in their day-to-day. They feel really down, they have trouble breathing, and it really just helps them live the life that they wanna lead. And so for us to see now in this randomized trial that's been presented with TRILUMINATE, to see high-quality data where that you can treat tricuspid regurgitation in a randomized trial, get safe results, and have significant TR reduction with meaningful quality of life, wow! I mean, that's just fantastic for patients and something we love. Ultimately, down to the community and the regulators, they're gonna keep looking at the benefit and risk trade-off to make the decisions that they need to make. But we continue to be super excited by what these therapies are doing for tricuspid patients. What we are, in addition to what Daveen said, you know, what we like about where we are today is, in the past few years, it was only about TEER, it was only about repair. So physicians didn't have a lot of options. And what we are doing is now progressing with our vision to being able to offer physicians a toolbox, so they can decide what therapy for what patient, for what anatomy. And so that's big progress to where we were a few years ago, even a few months ago. So a great progress here, and I see more to come. No, thanks for that. Just one follow-up on just the U.S. sales strategy and having two separate teams for TAVR and for the TMTT franchise. Just wanted to hear about how that's going. And I guess the concern is just, are you missing any cross-selling synergies that you could potentially garner from the TAVR sales reps and their deep relationships with some of these interventional cardiologists? Thanks for taking the question. Thank you. So what about, you know, I ask, you know, Larry, who is leading that, you know, every day to comment on this? Yeah, you know, it's funny, when we launched TAVR in the U.S., if you'll remember, half of our procedures were transapical, and people were like, you know, "Hey, you already have a selling organization that's selling to surgeons. Why are you developing this whole new sales organization? You could get a lot of synergy." But it's really all about providing that high touch model and that level of expertise, and we built out a completely separate sales force for THV, and I don't think there's a day we look back on that and think that that was a bad decision. I think we feel that that was the right decision for the therapy. You know, mitral patients are different than aortic patients, and, you know, if you ask your clinical specialists and your salespeople to try to be experts in 10 therapies, they're gonna be generalists in all of them and not experts. And I think one of the reasons we've had the success we've had in TAVR is, you know, when... I think our average field clinical specialist supports about 1,200 cases a year. And so you bring that level of expertise to every case, and, you know, we really drive differentiated outcomes for patients, which I think what's driven the therapy and what's driven our leadership, and we like that model a lot. We think it's been hugely successful. Just because our teams sit in different organizations doesn't mean they don't talk. You know, Daveen and I talk a lot, you know, I have surgical structural heart now, but I talk to Wayne, our general manager of that, all the time. We look for where there are opportunities for us to work together, but at the same time, we wanna make sure we have focus on these new therapies, and we bring the highest level of expertise possible, so we drive the best outcomes for patients possible, because we believe that is what's gonna drive long-term the success of our, of our franchises. I'll add one thing on that. This is Daveen. Even here at TCT, as I talk to physicians, the one thing I consistently hear from physicians is they so appreciate our comprehensive high touch model. They love that the Edwards person, who is so deep in the mitral tricuspid space, and that's all they breathe, live, and really think about. So they can offer the best possible advice to the physician, the best possible collaboration to ensure the best possible patient result. I just love seeing that this week as I talk to physicians. That's helpful. Thanks so much. Our next question comes from Travis Steed with Bank of America. Please state your question. Hey, thanks for taking the question. Maybe just to clarify, one clarification, when I add your Q4 guide of $0.60-$0.66, I'm getting to a full year of $2.47-$2.53, which is different than your full year guidance. So I don't know if there was a restatement or just wondering, maybe my math is off. Just wanted to clarify that, if you don't mind. No, your math is spot on. At the midpoint of the range, that's exactly what it implies. And so, take the midpoint, it ends up at the lower end of that $2.50-$2.60 range, but still within the range. Okay, got it. And then the comment on U.S. and OUS growth rates being comparable, is that referring to constant currency or reported? It looks like OUS is a little bit lighter this quarter, and just wanted to make sure I understood everything going on in OUS and some of the Japan comments and what's going on in Japan. No, all those growth rates we talked about were underlying constant currency growth rates. Okay, that's, that's fair. And then my last question was on 2024. I know you're not gonna talk a lot about 2024, but curious if you think you can still, you know, hold share stable with new competition coming in, or if you think it's fair to assume, you know, something less than the market growth rates in 2024? Yeah, it's Scott. You know, let's hold off on that question about share and the environment, new product introductions and all kind of stuff. There's a lot that we expect to happen in 2024, and we'll look forward to getting into all of those details and forecasts when we get together at our investor conference in December. Great. Great. Thanks a lot. Our next question comes from Joanne Wuensch with Citibank. Please state your question. Good afternoon, and thank you for taking the question. Two of them. I know you don't want to talk about 2024, but last year you did a great job of helping us understand the impact of FX on gross margins, and it sounds like you're gonna have an FX headwind next year. Can you sort of level with us, for how to think about gross margins next year? Yeah, I hate to do this to you, Joanne, but again, we're gonna have to hold off until we get to December. Really all we can say right now is that we think we're gonna see some pressure on the top line reported sales dollars, it won't impact our underlying growth rates. And the reported sales dollars headwind is gonna flow right down to earnings per share. Now, again, that's not current foreign exchange rate. So when we get to December and we lay out our full year guidance for 2024, and we'll go through all the lines of the P&L and take you through all the detail, but at this point, we really can't tell you more. Okay. My follow-up question, which is completely unrelated, is you did another quarter of double digit surgical valve revenue, and I'm curious what's helping to drive that and how much of it is maybe an upcharge from RESILIA versus underlying demand? Thank you. Yes, so let me start here. You know, so 11, you know, 11%, obviously, you know, we are very pleased. You know, I don't know if you remember, but a few years ago, you know, nobody, you know, believe in surgical, and we believe in surgical because we have been a pioneer here. We have been a great innovator, and, you know, our innovation is paying off. You know, what we see, you know, in, in Q3 again, like in 2023, we see a balanced combination between adoption of our RESILIA platform, premium pricing, and also the procedural growth. So altogether, but it is very balanced between procedural growth and our premium technology. Yeah, I'll just add it. It's... You know, we'll try to bring this to life a little bit at the investor conference. I almost feel like when we have a good surgical quarter, that you guys get mad at us because, you know, you think it comes at the expense of TAVR. And I'll tell you, as the guy that runs both those business units, that gets really frustrating after a while, and my new GM is really mad about it. So if, but what you have to understand is our surgical business isn't 100% aortic stenosis. Our surgical business treats aortic, we treat mitral, and even in the aortic space, we don't just treat aortic stenosis, we treat aortic regurgitation. You know, we have products like Konect, where we're treating aortic aneurysm disease. You know, we have repair products, replacement products, so there's just a lot more that goes into that business than aortic stenosis. So thinking that it's a zero-sum game between the two businesses just isn't the right way to think about it. Thank you. Our next question comes from Matt Miksic with Barclays. Please state your question. Hey, thanks. Thanks for taking the question. So, one, if I could, on, sometimes, Scott and Bernard, you're able to offer some color as to what, you know, how the different types of centers in the US have been performing. You mentioned staffing stable. Any color as to, you know, which large, small or, you know, size centers were additive to growth and in what ways? And then I have one follow-up. Yeah, maybe, you know, I'm going to ask Larry to comment on that with... Yeah. You know, we look at this every quarter, and I will just tell you, just even internally amongst us, we sort of see the growth rates by segment, and then we sort of make up the reasons for why we think they're different a little bit. I will tell you, during COVID, we saw trends that said when COVID spiked, people tended to stay a little bit closer to home, and we saw maybe some of our smaller centers grow more and larger centers would grow less. Then as COVID waned, we'd see larger centers kind of return to higher growth. I think this quarter we probably saw a little bit more growth in the higher, in the bigger centers than the smaller centers. Really, I think it's getting a little bit negligible when we're kind of returning to a little bit of sense of normalcy as it relates to growth across center size. That's helpful. Thank you for that. And then just one follow-up on just maybe a segment of the market that I've got to be getting bigger, I guess, by this point, but looking forward, being the only valve on the market with a valve-in-valve indication, you know, how big is that now? And how important is that? You know, we talk a lot about the expanding indications into, you know, asymptomatic and moderate AS patients over the intermediate long term. But does valve-in-valve become a factor that you can talk more about? Or maybe help us understand how that factors into your growth or the general growth in the market at this point. Yeah, I think it's a good question. I think valve- and- valve isn't a huge part of our offering right now. It's not a big driver for us. We do TAV in TAV, so TAV in failed biological surgical valves. And, you know, as TAVR came online, we saw more and more biological valve usage in younger patients because they knew they would have this TAVR option down the road. So we think that that's gonna be, you know, as these patients live longer, you know, obviously our surgical valves are very durable, but that was the whole basis for INSPIRIS, was creating a valve that would be a great platform for their TAVR procedure down the road, and that's the whole basis for it, and we think that will pay dividends later. You know, we just got the low-risk approval, you know, it's still fairly new for us. It's, you know, it's not something that's been around for forever. But the more and more patients that are younger that are getting TAVR, eventually those patients will come back and need a second procedure. And, you know, so for us, having a TAV in TAV option, it just feeds directly into our lifetime management strategy, which is putting in a first valve and ensuring that you have a strategy for that next intervention, and that's true whether it's INSPIRIS as your first valve or whether it's a SAPIEN 3 as your first valve. We wanna make sure we have an option for that patient when they come back, and that's what's great about both of our surgical and TAVR platforms, is they're both really a great host for that future valve. We do think, you know, as you advance down the road, that TAV in TAV will become a bigger contributor to our growth over time. Thanks so much. Our next question comes from Danielle Antalffy with UBS. Please state your question. Hi, good afternoon, guys. Thanks so much for taking the question. I was just wondering if I could follow up actually on the data, the five year data we saw yesterday. And, Larry, if there's any read that we can make or something that we saw in the data that could give us more confidence in the upcoming asymptomatic data readout, or is that just too difficult to, you know, to take anything from yesterday and apply it to that trial? Yeah, you know, I, I appreciate everybody's trying to get an early read on, on early TAVR, and I don't think there's, I don't think there's anything that's really from this data that I... And, and I haven't even, you know, we haven't even broke apart the early TAVR data, so I don't even know anything about the data set yet to even talk about, and even if I did, I couldn't tell you. I think just broadly speaking, the fact that we show excellent durability out at five years with no durability signal whatsoever, if AS, the asymptomatic trial, is successful, which, you know, we obviously hope it is, but if that trial's successful, it just takes one more burden away from people saying, "Do I want to treat people earlier in the disease state?" And I think the more durability data we can put on the board will help make that, if, you know, if that trial is successful and we do get the indication, that that'll be one barrier that's removed. So I think the long-term data continuing to build on the durability and safety and long-term results of the platform just continue to be important, and it's gonna be important long term for the PROGRESS trial. You know, if you're gonna treat people with moderate disease down the road, you need to make sure you have a durable platform and that it has options, you know, down the road for these patients. So I think it all is complementary, but I don't think anything about this trial informs the early TAVR results. Okay, got it. And then just a quick question on, you know, Bernard, you mentioned, there's still a lot of these patients untreated out there. I mean, as far as Edwards' progress on getting those patients off the couch, into their physician's office, diagnosed, and referred for TAVR, I mean, where are we in that process? You know, you guys spent a lot of time at the Analyst Day last December. I imagine we'll get an update, too, in December, in a few weeks here. But just curious what you can say about, are you seeing any real traction in some of the, direct-to-consumer campaigns, things like that? Thanks so much. So, you know, thanks for the question. You know, we, we see, you know, this, this initiative as super important, you know, to us. You know, we have the right platform, we have the right science, so how can we get even more patients? And, we have done in the last, I want to say years, you know, maybe, you know, three to four years, you know, a lot of initiative, a lot of pilots. We learn a lot. This year, we scale some of the initiative, and so we are going to talk more about it in December. You know, Larry and his team are going to talk about it. But we feel like, you know, we have some interesting learning, and we believe that, you know, we are starting to see some impact also. So we feel, excited about the potential of that. It is why, you know, when we say that we believe the future is even more exciting, it is because of this reason. In addition, obviously, you know, asymptomatic and moderate indication will add, you know, to all of this. But, Larry, you want to add anything? Sure. You know, I think it's one thing that I think people are missing a little bit is, it's not like we just started doing patient activation stuff, you know, last year or, you know, in the last two years. I mean, we go all the way back to starting a website with a lot of educational information for patients, even things like how to find a TAVR center and, you know, questionnaires and patient information kits. So we've been doing a lot of things over the last several years, that I think is one of the reasons the market has grown and developed the way it has. So I think a lot of our digital and patient activation efforts are paying dividends right now. Now, the deeper you go into the prevalence pool, the harder it gets and the more activation you have to do. So it's sort of... You know, I found a light switch. It's a never-ending journey that you're gonna do to continue to build on the last program with additional programs to try to get people activated. And I'll tell you, we have a lot of work streams, and we're looking forward to maybe getting into a little bit more detail at the investor conference and trying to show you a little bit about other things that we're working on. But we have a number of pilots, and we have a lot of very mature programs at the same time that we think help us a lot. Thank you. And our next question comes from Pito Chickering with Deutsche Bank. Please state your question. Hey, good afternoon, guys. Previously, you mentioned that the TAVR market share is stable. You look at competitive accounts with hospitals and doctors that use both SAPIEN and CoreValve. We're seeing market changes in those accounts where RESILIA is competing against FX. Yeah, I think market share has been pretty stable. I don't think we've seen big shifts or big changes. You know, we're very excited about Resilia, and I think it does give people increased confidence in going into younger, lower-risk patients. So, you know, we feel good about that, but you know, maybe we can try to update that a little bit more at the investor conference. But again, you know, I think overall, I think share has been generally pretty stable. Okay, great. And then a quick follow-up. TAVR, you said that procedure growth was the same as revenue growth, but was there any benefit from positive pricing from Resilia? I thought that would help to drive revenue growth above volume growth. Thanks so much. There was a little benefit, but it wasn't the big driver of our growth. Great. Thank you. Thank you. Ladies and gentlemen, that's all the time we have for questions today. I'll hand the floor back to management for closing remarks. Thank you. So let me close this meeting by saying, I am pleased with our performance in 2023. Beyond the numbers, I am excited with the progress we have made, reinforcing our TAVR leadership position with new clinical evidence and expanding our mitral and tricuspid patient reach with new approved technologies. As a result, you know, we are confident in our long-term strategy to help even more patients around the world. Thanks for your continued interest in Edwards. The IR team, Scott, and I welcome any additional question, any additional questions by phone. Thank you. Thank you. And with that, we conclude today's conference call. All parties may disconnect. Have a good day.